NCT06080256View on ClinicalTrials.gov

Extra Alirocumab in Addition to Statin Therapy in Asymptomatic Intracranial Atherosclerotic Stenosis (EAST-aICAS)

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

December 30, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Intracranial AtherosclerosisAtherosclerotic PlaqueStenosis
Interventions
DRUG

Alirocumab

alirocumab (75 mg every 2 weeks)

DRUG

Atorvastatin

Atorvastatin 20-40mg

Trial Locations (1)

210001

the First affiliated hospital of Nanjing Medical University, Nanjing

All Listed Sponsors
lead

The First Affiliated Hospital with Nanjing Medical University

OTHER